BioLineRx (BLRX) Misses Q2 EPS by 2c; Updates on Remaining FY16 Milestones

August 11, 2016 7:19 AM EDT
Get Alerts BLRX Hot Sheet
Trade BLRX Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

BioLineRx (NASDAQ: BLRX) reported Q2 EPS of ($0.09), $0.02 worse than the analyst estimate of ($0.07).

Expected upcoming significant milestones for remainder of 2016:

  • Initiation of Phase 2a study in pancreatic cancer, under immuno-oncology collaboration with Merck, following expected regulatory approval in Q3 2016
  • Second Phase 2a immuno-oncology study in pancreatic cancer, under collaboration with MD Anderson Cancer Center, expected to commence by end of 2016
  • Full set of data from Phase 2a study for BL-8040 in r/r AML to be presented at the Society of Hematologic Oncology (SOHO) annual meeting, September 7-10, 2016, in Houston, Texas
  • Partial results from Phase 2 study for BL-8040 in stem-cell mobilization for allogeneic transplantation expected by end of 2016
  • Regulatory submission for BL-7010 clinical efficacy study, for marketing purposes as food supplement
  • Expansion of commercial rollout of BL-5010 by Omega to additional countries and development of 2nd OTC indication for the product

For earnings history and earnings-related data on BioLineRx (BLRX) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Earnings, Guidance

Related Entities

Earnings

Add Your Comment